Follow the Money: Agios Pharmaceuticals, Inc.
Follow the Money highlights a newly funded bio/pharmaceutical company. This includes important insights into the featured company’s product pipeline, manufacturing and business relationships, and likely sourcing opportunities.
Agios Pharmaceuticals, Inc. is a U.S. public pharmaceutical company that develops drugs that target metabolic pathways critical to cancer cell growth, proliferation and survival. As reported in the December 18, 2014 issue of the PharmSource Lead Sheet, Agios raised $253 million in the closing of a secondary public offering.
- Agios was incorporated in Delaware in August 2007.
- Corporate Headquarters: Cambridge, Massachusetts – approximately 39,000 square feet of office and laboratory space.
- As of December 31, 2013, Agios had 96 employees, of whom 76 were engaged in R&D activities.
- Agios plans to use the proceeds to fund clinical and research development activities.
- The company relies on third parties, such as CROs, clinical data management organizations, medical institutions, and clinical investigators, to conduct clinical trials and preclinical testing.
- Agios does not own or operate manufacturing facilities and relies on third parties to produce product candidates for preclinical and clinical testing, as well as commercial sale.
- For all product candidates, the company intends to identify and qualify manufacturers to provide the API and fill-and-finish services prior to submission of any NDA to the FDA.
- Agios has no sales, marketing or distribution infrastructure.
- In April 2010, Agios and Celgene entered into a collaboration to discover and develop oncologic therapies based on Agios’ cancer metabolism research platform. Agios leads discovery, preclinical, and early clinical development for all cancer metabolism programs under the collaboration.1
|Product Candidate||Indication||Dosage Form||Status||Next Anticipated Step|
|Targets in Cancer Metabolism||Multiple Cancer Types||Unknown||Discovery||TBA|
|Targets in Rare Genetic Disorders of Metabolism||Multiple Monogenic Diseases||Unknown||Discovery||TBA|
|Hematologic Malignancies||Oral||Phase I||TBA|
|Hematologic Malignancies||Oral||Phase I||Global registration program in IDH2-mutant positive hematologic malignancies planned to initiate in 2015.|
|Solid Tumors||Oral||Phase I||TBA|
(R-type pyruvate kinase activator)
|Pyruvate Kinase Deficiency||Oral||Phase I||TBA|
|Solid Tumors||Oral||Phase I/II||TBA|
|(In $ thousands)||2013||2012|
|General & Administrative Expenditures||9,929||7,064|
|Total Operating Expenses||64,431||48,101|
1 Agios Pharmaceuticals, Inc. Annual Report, SEC.gov
|Agios Pharmaceuticals, Inc.||Key Officers|
|38 Sidney Street, 2nd Floor||David Schenkein, MD, CEO|
|Cambridge, MA 02139, USA||Scott Biller PhD, CSO|
|Phone: 617-649-8600||Chris Bowden, MD, CMO|
|Web: www.agios.com||Shin-San Michael Su PhD, SVP, R&D|
|Marion Dorsch PhD, VP, Biology|
Read more postings by Ryan